Patients with chronic liver disease complicated with sarcopenia requiring treatment with ginsen-yo-eito due to post-illness loss of strength, fatigue, anorexia, sweating, cold hands and feet, and anemia
Conditions
Interventions
For 6 months, Kracie Ninjin Yoeito is orally administered daily before or between meals in 2 divided doses of 7.5 g per day.
Sponsors
Bellland General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with at least one symptom of post-illness loss of strength, fatigue, anorexia, sweating, cold hands and feet, or anemia who receive treatment with Ninjin Yoeito 2. Patients who meet the criteria for sarcopenia proposed by the Japan Society of Hepatology (2nd edition) 3. Patients between 20 and 80 years of age, any gender 4. Patients who understand the contents of the consent document and are able to sign the consent form freely and voluntarily
Exclusion criteria
Exclusion criteria: 1. Patients under 19 years old and over 80 years old 2. cancer-bearing patient 3. Pregnant and lactating patients 4. Patients with poorly controlled ascites 5. Patients with poorly controlled hepatic encephalopathy 6. Patients with severely impaired renal function (eGFR<30 ml/min/1.73m2) 7. Patients with confirmed refusal to participate 8. Patients showing signs of alcohol dependence 9. Dementia (PS2 or higher) 10. Patients with psychosis who are regularly attending or hospitalized in a neuropsychiatric department and who are considered to be difficult to participate in the study 11. Other patients deemed ineligible by the investigators and subinvestigators 12. Patients with other addictions 13. Patients with intellectual disabilities 14. Patients with cerebral organic mental disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All scores on the Chronic Liver Disease Questionnaire | — |
Countries
Japan
Contacts
Public ContactYosuke Aihara
Bellland General Hospital gastroenterology
Outcome results
None listed